A property of gelatin sponge hemostatics is the ability to absorb upwards of 40 times its weight in blood or fluids, and its capacity to expand up to 200% in vivo. [22] This can be construed as a negative property in some settings. Another major advancement in the field of gelatin-based hemostatic agents came in the development of the product Floseal. Approved for commercial use in the US in 1999, Floseal combines human-derived thrombin with bovine-derived gelatin matrix granules which are mixed at the time of use. [24] The major evolution of this product is the liquid nature of Floseal vs gelatin sponge, as well as a novel crosslinking of the gelatin matrix granules that minimizes in vivo expansion of the product. [25] Although this is not an important property of a hemostatic agent in some surgical approaches, the liquid nature of the product does facilitate application, especially in minimally invasive surgery. As with gelatin sponge agents, Floseal is absorbable and well-tolerated. Rare reports of abscess formation or granuloma formation have been reported with the use of gelatin-based agents; however, some of these have been attributed to the radiologic appearance on postoperative imaging of gelatin sponges. [26],[27] Accessibility, ease of use, and effective hemostasis make gelatin-based hemostatic agents a popular tool in reducing surgical morbidity from blood loss.